A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Reference Study ID: ML39853 www.roche.com/about_roche/roche_worldwide.htm
- Phone Number: 888-662-6728 (U.S. only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Buenos Aires, Argentina, B1610BAL
- Productos Roche S.A. Quimica e Industrial, División Farmacéutica
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
- Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra).
- Have received at least one dose of atezolizumab as per local label and clinical practice.
Exclusion Criteria:
- Contraindicated atezolizumab therapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants with Adverse Events (AE)
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of participants with Confirmed Objective Response (ORR) of Complete Response (CR) or Partial Response (PR)
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
|
Overall Survival (OS)
Time Frame: Up to approximately 2 years.
|
Up to approximately 2 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML39853
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.